Dr. May T. Cho
Claim this profileUC Irvine Health/Chao Family Comprehensive Cancer Center
Studies Colorectal Cancer
Studies Rectal Cancer
7 reported clinical trials
17 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
Stage III
PD-L1 positive
2Rectal Cancer
Stage III
Stage IV
pMMR positive
Affiliated Hospitals
Clinical Trials May T. Cho is currently running
Tisotumab Vedotin
for Cancer
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. * In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). * In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. * In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part D, participants will be given treatment on Day 1 of every 3-week cycle. Participants in Part D will get tisotumab vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin * In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. * In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin.
Recruiting1 award Phase 216 criteria
Nivolumab + Standard Treatment
for Colorectal Cancer
This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and whose tumor has a mutation in a gene called BRAF. Encorafenib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the BRAF gene. It works by blocking the action of mutated BRAF that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with encorafenib and cetuximab may be more effective than encorafenib and cetuximab alone at stopping tumor growth and spreading in patients with metastatic or unresectable BRAF-mutant colorectal cancer.
Recruiting1 award Phase 2
More about May T. Cho
Clinical Trial Related6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments May T. Cho has experience with
- Nivolumab
- Carboplatin
- Cisplatin
- Epacadostat
- Tisotumab Vedotin
- Pembrolizumab
Breakdown of trials May T. Cho has run
Colorectal Cancer
Rectal Cancer
Cancer
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does May T. Cho specialize in?
May T. Cho focuses on Colorectal Cancer and Rectal Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is May T. Cho currently recruiting for clinical trials?
Yes, May T. Cho is currently recruiting for 5 clinical trials in Orange California. If you're interested in participating, you should apply.
Are there any treatments that May T. Cho has studied deeply?
Yes, May T. Cho has studied treatments such as Nivolumab, Carboplatin, Cisplatin.
What is the best way to schedule an appointment with May T. Cho?
Apply for one of the trials that May T. Cho is conducting.
What is the office address of May T. Cho?
The office of May T. Cho is located at: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California 92868 United States. This is the address for their practice at the UC Irvine Health/Chao Family Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.